Search For a Provider Facebook Twitter Instagram YouTube ES View the Patient Toolkit


Peyronie’s Disease: More Men Receiving CCH Injections

Peyronie’s Disease: More Men Receiving CCH Injections Nowadays, more men with Peyronie’s disease are being treated with injections of collagenase clostridium histolyticum (CCH) than surgery, according to recent research.

Peyronie’s disease is characterized by plaques of hardened scar tissue that form on the penis, just below the skin’s surface. The plaques make the penis lose some of its flexibility. As a result, the penis starts to bend. Sometimes, the curve is so severe that intercourse is difficult. Men with Peyronie’s disease may also experience pain and erectile dysfunction (ED).

Surgery to correct the curve is a common treatment. CCH injections, which are targeted directly at the plaques, were approved in 2014.

The study findings are based on insurance claims data for 36,156 men who were first diagnosed with Peyronie’s disease between 2011 and 2017. Diagnosis rates did not change much during that period.

In 2014, the treatment rate with either CCH or surgery was 9.8%, but the rate rose to 15.5% by 2017, reflecting an increase in men undergoing CCH injections. After CCH injections were approved, their use as a first-line treatment increased an average of 1.6% per year.

The ratio of CCH to surgery as a first-line treatment increased from 1:1 in 2014 to about 2:1 by 2017.

1 2 Next » (page 1 of 2)